Method of thrombin time stabilisation for newborn piglets with anaemia

FIELD: medicine, veterinary science.

SUBSTANCE: method involves prescription of intramuscular injection of ferroglucinum by 150 mg (2 ml) twice over 10 day interval, intramuscular injection of phosprenyl thrice by different syringes into different points, by 0.08 ml/kg for the first time together with iron agent, by 0.07 ml/kg over five days after the first injection, by 0.05 ml/kg for the third time together with the second injection. Additionally, 0.016 ml/kg of gamavit is injected intramuscularly once per day for six days beginning from the first ferroglucinum injection.

EFFECT: possible thrombin time stabilisation for newborn piglets with anaemia.

1 ex

 

The invention relates to biology and veterinary medicine.

Analogues of the proposed method to normalize trombonology time in newborn piglets with anemia does not exist.

In the literature there is information on the application of anemia in piglets feroglobin (Internal non-infectious diseases of farm animals. Edited Vmenyaemogo. M: "Agropromizdat", 1991. - 576 S.).

As an effective stimulant of life growing organism in modern veterinary medicine applied fosprenil - drug-based phosphate polyprenols, obtained from the needles, and gamavit - complex balanced means on the basis of the placenta, containing nukleinat sodium, set of amino acids, vitamins and salts (Deeva AV, Salakhova Z.A., Lobova et al. improve the safety and productivity of pigs when using fosrenol and amavita. // Veterinary medicine. - 2006. No. 4. - s-15).

However, never before medical complex consisting of feroglobin, fosrenol and guavita, was not used in newborn piglets with anemia to normalize thrombin time.

The aim of the invention is to increase the efficiency of correction of thrombin time in newborn piglets with anemia.

The essence of the proposed method is that for optimization thrombin time newborn piglets with anemia on nachatsja feroglobin 150 mg (2 ml) intramuscularly, dmocrate with an interval of 10 days, fosprenil intramuscularly, three times in different syringes at different points, the first time of 0.08 ml/kg simultaneously with the preparation of iron, for the second time in a dose of 0.07 ml/kg five days after the first injection feroglobin, third time in a dose of 0.05 ml/kg simultaneously with the second injection feroglobin and gamavit 0,016 ml/kg intramuscularly once a day for six days, starting with the first injection feroglobin.

The method allows to normalize thrombin time in newborn piglets with anemia 5 days after completion of treatment, translating it to a level close to that of healthy pigs. When you follow the advice of the proposed method can be maintained in subsequent thrombin time in an optimal state, which will allow the newborn piglets with anemia significantly reduce the risk of thrombotic complications, to improve the health of the herd, improving trophic and their tissues, and consequently to accelerate growth, increase the amount of meat products and to reduce mortality.

The inventive method is carried out as follows.

For the diagnosis of newborn piglets with anemia violations of the thrombin time is its evaluation according to the following procedure.

The principle of the method: determine the clotting time of the plasma under the influence of thrombin, standardized by activity in normal control the plasma. Thrombin test characterizes the kinetics of the final stage of blood coagulation is the rate of conversion of fibrinogen to fibrin.

Used reagents: 1. Tris buffer, 0.05 M (or Michaelis buffer), pH 7.3 to 7.4. 2. A solution of thrombin in buffer activity 14-16 sec. The working solution of the reagent prepared in a plastic or silikonizirovannoj vitro and used the day of the examination. Stored at room temperature.

The research material is citrate BTP.

To 0.2 ml of the investigated plasma heated in a water bath at +37°C for 1 min, add 0.2 ml of thrombin (to which research should have a temperature not higher than +18-25°). Immediately include stopwatch and note the clotting time.

The determination is performed manual or coagulometer.

The results are expressed in seconds, comparing the clotting time in normal control (reference) and investigated the plasma. Normal thrombin time (TV) is 14-16 sec. Anemia in piglets observed acceleration of the TV.

When accelerating TV in newborn piglets with anemia need for treatment according to the stated method: feroglobin 150 mg (2 ml) intramuscularly, dmocrate with an interval of 10 days, fosprenil intramuscularly, three times in different syringes at different points, the first time of 0.08 ml/kg simultaneously with the preparation of iron, for the second time in the lake of 0.07 ml/kg five days after the first injection feroglobin, third time in a dose of 0.05 ml/kg simultaneously with the second injection feroglobin and gamavit 0,016 ml/kg intramuscularly once a day for six days, starting with the first injection feroglobin.

Example. The newborn Piglet No. 11 with anemia impaired erythropoiesis with signs of decreased levels of iron in his body, accompanied by a change of blood. Thus, the amount of hemoglobin it was 82,0 g/l, erythrocytes 4,05×1012/l, sideration of 1.0% when the level of iron in serum of 12.0 µmol/l increase in total iron-binding capacity of serum to 68.2 mmol/L. When the survey was detected acceleration of thrombin time (12 sec). The pig was assigned feroglobin 150 mg (2 ml) intramuscularly, dmocrate with an interval of 10 days, fosprenil intramuscularly, three times in different syringes at different points, the first time of 0.08 ml/kg simultaneously with the preparation of iron, for the second time in a dose of 0.07 ml/kg five days after the first injection feroglobin, third time in a dose of 0.05 ml/kg simultaneously with the second injection feroglobin and gamavit 0,016 ml/kg intramuscularly once a day for six days, starting with the first injection feroglobin.

5 days after the end of treatment for pig normalized red blood count hemoglobin he was to 118.0 g/l, erythrocytes 5,10×1012/l, sideri the comrade of 8.0% at the level of iron in serum 21,0 µmol/l with a decrease in the total iron-binding capacity of serum to 35.9 μmol/l, achieved a complete normalization of thrombin time (15 sec), remaining stable thereafter.

Using the proposed optimization technique thrombin time in biology and veterinary medicine will help to avoid vascular complications in newborn piglets with anemia, to improve the health of the herd, to reduce mortality and increase the amount and quality of meat products and get these animals healthy offspring.

The method of normalization of thrombin time in newborn piglets with anemia, including application feroglobin 150 mg (2 ml) intramuscularly, dmocrate with an interval of 10 days, fosrenol intramuscularly, three times in different syringes at different points, the first time of 0.08 ml/kg simultaneously with the preparation of iron, for the second time in a dose of 0.07 ml/kg five days after the first injection feroglobin, third time in a dose of 0.05 ml/kg simultaneously with the second injection feroglobin and amavita 0,016 ml/kg intramuscularly once a day for six days, starting with the first injection feroglobin.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly oncology, and can be applied in complex rectus cancer treatment with removed two-end colostomy. Invention substance involves sampling of 200 ml of patient's autoblood in post-operation period after two-end sigmostoma removal. Then autoplasma is separated from blood by centrifugation method, 50 ml of autoplasma and 1000 mg of 5-fluorouracil is placed in first bottle and remaining blood and plasma elements are placed in the second bottle. Bottles are incubated separately for 40 minutes at 37°C. Then autoplasma with 5-fluorouracil from the first bottle is administered intratestinally to non-functioning intestine of two-end colostoma; autoblood from second bottle is reinfused intravenously by drop infusion, followed by first radiation treatment session. Intratestinal chemotherapy with autoplasma with intravenous autohemotherapy is repeated one time per week during the whole radiation therapy course.

EFFECT: enhanced efficiency of radiation treatment due to direct effect of 5-fluorouracil on tumour and to radio-sensibilising effect; possible transfer of patients to respectable condition and reduced radiation complication rate.

2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly oncology, and can be applied in complex rectus cancer treatment with removed two-end colostomy. Invention substance involves sampling of 200 ml of patient's autoblood in post-operation period after two-end sigmostoma removal. Then autoplasma is separated from blood by centrifugation method, 50 ml of autoplasma and 1000 mg of 5-fluorouracil is placed in first bottle and remaining blood and plasma elements are placed in the second bottle. Bottles are incubated separately for 40 minutes at 37°C. Then autoplasma with 5-fluorouracil from the first bottle is administered intratestinally to non-functioning intestine of two-end colostoma; autoblood from second bottle is reinfused intravenously by drop infusion, followed by first radiation treatment session. Intratestinal chemotherapy with autoplasma with intravenous autohemotherapy is repeated one time per week during the whole radiation therapy course.

EFFECT: enhanced efficiency of radiation treatment due to direct effect of 5-fluorouracil on tumour and to radio-sensibilising effect; possible transfer of patients to respectable condition and reduced radiation complication rate.

2 ex

FIELD: medicine; physiotherapy.

SUBSTANCE: ultrasonic inhalations of 10 ml solution of 1% placenta hydrolyzate are applied at temperature of solution 35°C within 10 minutes. Procedure is applied in the morning on an empty stomach, or 40-60 minutes after eating. It is followed with scanning laser therapy with infra-red laser radiation from laser scanning physiotherapeutic stimulator LSPS-03.2IR. Output power at light guide end is 2 mWt, power flux density is 50 mWt/cm2. While exposure the patient is positioned lying on stomach, thus effecting paravertebral fields to the right and to the left at level D3-D9, within 3 minutes per each field. Then while the patient is positioned lying on back, liver region is exposure within 8 minutes. Course is 10 daily procedures.

EFFECT: normalised eliminative properties of epithelial barrier of a respiratory tract and local immunity of airway mucous membrane.

3 tbl, 2 ex

FIELD: medicine; experimental neurology.

SUBSTANCE: offered method of brain cortex motoneurons growth stimulation for growing mammals in experiment involves daily introduction of adrenal cortex extract within total course 5 weeks. Herewith pig's adrenal cortex extract is introduced in single dose 0.5 ml per 100 g of body weight. Offered is application of pig's adrenal cortex extract as brain cortex motoneurons growth stimulator for growing organism.

EFFECT: extended range of products for brain cortex motoneurons growth stimulation and possibility to use available product.

2 cl, 1 tbl

FIELD: medicine; experimental neurology.

SUBSTANCE: offered method of brain cortex motoneurons growth stimulation for growing mammals in experiment involves daily introduction of adrenal cortex extract within total course 5 weeks. Herewith pig's adrenal cortex extract is introduced in single dose 0.5 ml per 100 g of body weight. Offered is application of pig's adrenal cortex extract as brain cortex motoneurons growth stimulator for growing organism.

EFFECT: extended range of products for brain cortex motoneurons growth stimulation and possibility to use available product.

2 cl, 1 tbl

FIELD: medicine; oncology.

SUBSTANCE: thoracic lymphatic duct is drained with lymph collected, incubated at temperature 37°C within 24 hours with Ronkoleukine 1 million ME (IL-2). It is followed with combined autolymphoimmunotherapy and autolymphochemotherapy.

EFFECT: stimulation ensured by generation of lymphokine-activated killers, antineoplastic cell-mediated immune response stimulating tumour lysis with low toxicity and good tolerance to chemotherapy.

3 cl, 2 ex

FIELD: medicine; oncology.

SUBSTANCE: method is implemented through sampling blood in amount 150 ml, producing plasma 50 ml and erythrocytic solution 100 ml, separating plasma into 2 bottles. The first bottle with autoplasma 30 ml is added with fluorouracil at 1000 mg/m2 and cyclophosphan 1000 mg/m2. The second bottle with autoplasma 20 ml is added with methotrexate 30-50 mg/m2. The bottles are incubated at t 37°C within 20-30 minutes. Autoplasma preparations at first of the first bottle, then of the second bottle are introduced paratumourally and directly into tumour node towards lymph flow. Furacilin alcohol aseptic dressing is applied on the breast. Residual erythrocytic solution is added with leukovorin dosed 50 mg/m2, incubated and introduced intravenously drop-by-drop; if necessary interstitial autoplasmochemotherapy procedure is performed again.

EFFECT: stabilised process and patients' transfer to resectable condition due to involution of tumour and regional metastases, reduced concurrent reactions and complications within treatment, reduced number of early relapses and remote metastases.

2 dwg, 1 ex

FIELD: medicine; oncology.

SUBSTANCE: method is implemented through sampling blood in amount 150 ml, producing plasma 50 ml and erythrocytic solution 100 ml, separating plasma into 2 bottles. The first bottle with autoplasma 30 ml is added with fluorouracil at 1000 mg/m2 and cyclophosphan 1000 mg/m2. The second bottle with autoplasma 20 ml is added with methotrexate 30-50 mg/m2. The bottles are incubated at t 37°C within 20-30 minutes. Autoplasma preparations at first of the first bottle, then of the second bottle are introduced paratumourally and directly into tumour node towards lymph flow. Furacilin alcohol aseptic dressing is applied on the breast. Residual erythrocytic solution is added with leukovorin dosed 50 mg/m2, incubated and introduced intravenously drop-by-drop; if necessary interstitial autoplasmochemotherapy procedure is performed again.

EFFECT: stabilised process and patients' transfer to resectable condition due to involution of tumour and regional metastases, reduced concurrent reactions and complications within treatment, reduced number of early relapses and remote metastases.

2 dwg, 1 ex

FIELD: medicine; oncology.

SUBSTANCE: method involves introduction of dendritic cells (DC) induced in vitro to start aging and characterised with the ability to grasp and process antigene in vivo. Pharmaceutical composition under the invention contains these DC combined with pharmaceutically acceptable introduction carrier.

EFFECT: induction of antitumor immune response.

32 cl, 3 tbl, 7 ex

FIELD: medicine; oncology.

SUBSTANCE: method involves introduction of dendritic cells (DC) induced in vitro to start aging and characterised with the ability to grasp and process antigene in vivo. Pharmaceutical composition under the invention contains these DC combined with pharmaceutically acceptable introduction carrier.

EFFECT: induction of antitumor immune response.

32 cl, 3 tbl, 7 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to compound of the formula (I) possessing inhibitory effect on production of interleukin-12 (IL-12) wherein R1 represents group of the formula , aryl or heteroaryl; each among R2 and R4 represents independently hydrogen atom, (C1-C6)-alkyl or (C1-C6)-alkoxy group; R3 represents Rc, alkenyl, -ORc, -OC(O)Rc, -SRc, -NRcCORd, -NRcC(O)ORd, -NRcC(O)NRcRd, -NRcSO2Rd, -CORc, -C(O)ORc or -C(O)NRcRd; R5 represents hydrogen atom (H); n = 0, 1, 2, 3, 4, 5 or 6; X represents oxygen atom (O) or -NRc; Y represents a covalent bond. -CH2, O or -NRc; Z represents nitrogen atom (N); one of values U and V represents N and another represents -CRc; W represents O, sulfur atom (S) or -S(O)2 wherein each radical among Ra and Rb represents independently H, (C1-C6)-alkyl, aryl or heteroaryl; each radical among Rc and Rd represents independently H, (C1-C6)-alkyl, phenyl, heteroaryl, cyclyl, heterocyclyl or (C1-C6)-alkylcarbonyl wherein term "aryl" relates to hydrocarbon cyclic system (monocyclic or bicyclic) comprising at least one aromatic ring; term "heteroaryl" relates to hydrocarbon cyclic system (monocyclic or bicyclic) comprising at least one aromatic ring that comprises at least one heteroatom, such as O, N or S as a part of cyclic system and wherein other atoms mean carbon; term "cyclyl" and "heterocyclyl" relate to partially or completely saturated monocyclic or bicyclic system comprising from 4 to 14 carbons in rings wherein heterocyclic ring comprises one or some heteroatoms (for example, O, N or S) as part of cyclic system and wherein other atoms mean carbon, and under condition that when X represents -NH, Y represents a covalent bond, n = 0, and R3 represents H or CH3 then R1 doesn't mean thiazolyl or pyrimidinyl. Also, invention relates to a pharmaceutical composition and a method for treatment of disorder associated with hyperproduction of interleukin-12.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

49 cl, 43 ex

FIELD: animal science.

SUBSTANCE: the suggested preparation contains disodium or dipotassium salt of ethylenediamine-N,N1succinic acid, iron (III), manganese (II), zinc (II), copper (II), cobalt (II), iodine (I), selenium (IV) and water at the following ratio of components, weight%: disodium or dipotassium salt of ethylenediamine-N,N1disuccinic acid 25.1-57.5; iron (III) 0.5-5.5; manganese (II) 0.25-4.9; zinc (II) 0.05-2.0; copper (II) 0.10-0.55, cobalt (II) 0.05-0.3, iodine (I) 0.01-0.08, selenium (IV) 0.01-0.06, water - the rest. The preparation suggested enables to increase vitamin full value of feedstuffs.

EFFECT: higher efficiency.

4 ex, 4 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes water-soluble iron-carbohydrate complexes containing 10-40 wt.-% of iron. Complexes can be prepared from ferric (III) salt aqueous solution and oxidation product aqueous solution of one or more maltodextrins with hypochlorite aqueous solution at alkaline pH value. In using one maltodextrin its dextrose equivalent is from 5 to 20, and in using mixture of maltodextrins the dextrose equivalent is from 5 to 20 and dextrose equivalent of each maltodextrin as component of mixture is from 2 to 40. Also, invention describes a method for preparing this complex and medicinal agents used in treatment and prophylaxis of states associated with iron deficiency.

EFFECT: improved preparing method, valuable medicinal properties of complexes.

15 cl, 1 tbl, 8 ex

FIELD: veterinary science.

SUBSTANCE: invention relates to a composition used in prophylaxis and treatment of anemia in agricultural animals and poultry that comprises a mixture of chelates of iron, copper, zinc, cobalt, sodium, calcium with ethylenediamine-N,N'-disuccinic acid in the following ratio of components, wt.-%: copper chelates with ethylenediamine-N,N'-disuccinic acid, 0.45-0.60; zinc chelates with ethylenediamine-N,N'-disuccinic acid, 1.40-1.45; cobalt chelates with ethylenediamine-N,N'-disuccinic acid, 0.075-0.08; sodium chelates with ethylenediamine-N,N'-disuccinic acid 42.0-44.0; calcium chelates with ethylenediamine-N,N'-disuccinic acid, 12.0-13.0, and iron chelates with ethylenediamine-N,N'-disuccinic acid, the balance. Agent provides enhancing the blood hemoglobin content in animals by 28% as compared with animals receiving neither anti-anemic agents and by 12% as compared with animals receiving the preparation-analog.

EFFECT: enhanced effectiveness of composition.

4 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: composition comprises in % by mass: 2Na- or 2K-salt of ethylene diamine-N,N1-disuccinic acid 15.0-35.0; Na- or K-salt of amino acid 2.0-10.0; salts of iron (III) 0.6-3.0; manganese (II) 0.5-2.5; copper (II) 0.05-0.25; zinc (II) 0.3-2.5; cobalt (II) 0.005-0.05; selenium (IV) 0.01-0.03; iodine (I) 0.03-0.08; water takes the rest. Amino acid is selected from group containing glycine, alanine, valine, aspartic acid, glutamic acid, lysine, methionine, cystine, threonine and tryptophan.

EFFECT: eliminated microelement deficiency; stimulated erythropoiesis and nonspecific organism resistance.

2 cl, 10 tbl

FIELD: agriculture, animal husbandry, fur farming.

SUBSTANCE: invention relates to preparations used in prophylaxis and treatment of domestic and agricultural animals and for maintaining trace elements composition of fodders. The preparation allows balancing the nutrition diet for animals with the optimal ratio of trace elements providing prophylaxis of many diseases. Proposed preparation comprising complex of iron, manganese, copper, cobalt, selenium and zinc with ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt and water comprises additionally iodine in the following ratio of components: ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt, 15-25; iron (III), 1.5-5.5; manganese (II), 0.25-3.0; copper (II), 0.12-0.55; cobalt (II), from above 0.05 to 0.3; zinc (II), 0.05-1.5; selenium (IV), from above 0.03 to 0.06; iodine (I), 0.01-0.08; water, the balance.

EFFECT: improved and valuable properties of preparation.

1 cl, 4 tbl

FIELD: pharmaceutics, veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating hypomicroelementosis in different farm and domestic animals, furred animals, and, also, for enhancing the growth in animals, and treating a number of specific diseases and, also, for maintaining microelemental composition of feedstuffs. The suggested preparation includes chelated complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with organic ligand of complexone type and water. According to the innovation as a chelation ligand it contains trisodium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid at a certain ratio of components. The innovation provides to obtain preparation in soluble form being capable to be well digested by the animal.

EFFECT: higher efficiency.

FIELD: pharmaceutical engineering; medical engineering.

SUBSTANCE: method involves carrying out nuclear magnetic resonance tomography of human or animal blood circulation system containing chelating ion complexes of bivalent and valence three paramagnetic metals of (I)X-L-Y formula, where X is the polyamide carbonyl ligand residue and Y is the gallic acid derivative, .

EFFECT: high accuracy of diagnosis.

28 cl

The invention relates to pharmaceutical industry and relates to a method of producing iron-containing drug for the treatment and prevention of iron deficiency anemia in animals by the interaction of organic acids with gemostimuliruyuschee properties, isolated from extracts of peat, with a hydroxide of iron (11), selected from water-soluble salts of iron (11) the deposition of the alkaline solution with the subsequent laundering of water impurities

The invention relates to veterinary

FIELD: medicine, veterinary science.

SUBSTANCE: method involves prescription of intramuscular injection of ferroglucinum by 150 mg (2 ml) twice over 10 day interval, intramuscular injection of phosprenyl thrice by different syringes into different points, by 0.07 ml/kg for the first time together with iron agent, by 0.06 ml/kg over five days after the first injection, by 0.05 ml/kg for the third time together with the second injection. Additionally, 0.012 ml/kg of gamavit is injected intramuscularly once per day for ten days beginning from the first ferroglucinum injection.

EFFECT: possible alpha 2 antiplasmin level stabilisation for newborn piglets with anaemia.

2 ex

Up!